Generated by AI
SIGA Technologies Inc. is a commercial-stage pharmaceutical company focused on health security and infectious disease countermeasures. SIGA Technologies Inc. develops and commercializes antiviral medicines designed to address serious threats from orthopoxviruses and other emerging infectious diseases. Its lead product, TPOXX, is an oral antiviral treatment for smallpox, and the company also supplies an intravenous formulation for government use in public health preparedness settings. SIGA Technologies Inc. serves government customers and international markets through direct sales and distribution channels, making it a specialized participant in the biodefense and medical countermeasures segment of the pharmaceutical industry. Based in New York, SIGA Technologies Inc. concentrates on products that support outbreak response, national stockpiling, and treatment access for high-consequence viral diseases.
Website31 East 62nd Street
New York, NY, 10065
United States
The latest articles about SIGA.
SIGA Technologies Inc (SIGA) posted a Q3 net loss with no product sales, but secured a new five-year Canadian military contract worth up to $15 million while awaiting a delayed US government award.
Motley Fool Press Release.
Summary of May 20's posts. Generated by AI.
Summary of Aug 23's posts. Generated by AI.
Summary of Aug 16's posts. Generated by AI.
Summary of Aug 23's posts. Generated by AI.
Investors talking about SIGA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.